Influence of creatinine levels on survival in patients with veno-occlusive disease treated with defibrotide
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is one of the most fatal complications of hematopoietic cell transplantation (HCT), and defibrotide is the only curative drug. We conducted this study to confirm the survival rate of VOD/SOS patients diagnosed in Korea and assess the efficacy of defibrotide. Methods: Patients diagnosed with VOD/SOS after allogenic HCT between 2003 and 2020 were enrolled. We investigated day +100 survival rates and associated risk factors in patients who satisfied the modified Seattle criteria within 50 days of HCT. Results: A total of 110 patients satisfied the modified Seattle criteria, of which 65.5% satisfied the Baltimore criteria. Thirty- seven patients were treated with defibrotide. The day +100 survival rate of the 110 patients was 65.3%. The survival rates in patients who did not meet the Baltimore criteria and in those who did were 86.8% and 53.7%, respectively (p = 0.001). The day +100 survival rate of patients treated with defibrotide was 50.5%. Among the patients receiving defibrotide, those whose creatinine levels were more than 1.2 times the baseline had a significantly lower survival rate at 26.7% (p = 0.014). On multivariate regression analysis, the hazard ratio of satisfaction of the Baltimore criteria was 4.54 (95% confidence interval [CI], 1.69 to 12.21; p = 0.003). In patients treated with defibrotide, the hazard ratio was 8.70 (95% CI, 2.26 to 33.45; p = 0.002), when creatinine was more than 1.2 times the baseline on administration. Conclusions: The day +100 survival rate was significantly lower when the Baltimore criteria were satisfied, and when there was an increase in creatinine at the time of defibrotide administration.
Abstract
Background/Aims: Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is one of the most fatal complications of hematopoietic cell transplantation (HCT), and defibrotide is the only curative drug. We conducted this study to confirm the survival rate of VOD/SOS patients diagnosed in Korea and assess the efficacy of defibrotide. Methods: Patients diagnosed with VOD/SOS after allogenic HCT between 2003 and 2020 were enrolled. We investigated day +100 survival rates and associated risk factors in patients who satisfied the modified Seattle criteria within 50 days of HCT. Results: A total of 110 patients satisfied the modified Seattle criteria, of which 65.5% satisfied the Baltimore criteria. Thirty- seven patients were treated with defibrotide. The day +100 survival rate of the 110 patients was 65.3%. The survival rates in patients who did not meet the Baltimore criteria and in those who did were 86.8% and 53.7%, respectively (p = 0.001). The day +100 survival rate of patients treated with defibrotide was 50.5%. Among the patients receiving defibrotide, those whose creatinine levels were more than 1.2 times the baseline had a significantly lower survival rate at 26.7% (p = 0.014). On multivariate regression analysis, the hazard ratio of satisfaction of the Baltimore criteria was 4.54 (95% confidence interval [CI], 1.69 to 12.21; p = 0.003). In patients treated with defibrotide, the hazard ratio was 8.70 (95% CI, 2.26 to 33.45; p = 0.002), when creatinine was more than 1.2 times the baseline on administration. Conclusions: The day +100 survival rate was significantly lower when the Baltimore criteria were satisfied, and when there was an increase in creatinine at the time of defibrotide administration.
참고문헌 (27)
- Mohty M, "Sinusoidal obstruction syndrome", veno-occlusive disease : current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation(EBMT), 2015, pp.50, 781~789
- Coppell JA, "Hepatic veno-occlusive disease following stem cell transplantation : incidence, clinical course, and outcome", Biol Blood Marrow Transplant, 16, pp.157~168 (2010)
- Richardson PG, "The use of defibrotide in blood and marrow transplantation", Blood Adv, 2, pp.1495~1509 (2018)
- Corbacioglu S, "Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation", Expert Rev Gastroenterol Hepatol, 11, pp.885~898 (2017)
- Corbacioglu S, "Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation : an open-label, phase 3, randomised controlled trial", Lancet, 379, pp.1301~1309 (2012)
- Richardson PG, "Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure", Blood, 127, pp.1656~1665 (2016)
- Strouse C, "Defibrotide for treatment of severe veno-occlusive disease in pediatrics and adults : an exploratory analysis using data from the center for international blood and marrow transplant research", Biol Blood Marrow Transplant, 22, pp.1306~1312 (2016)
- Corbacioglu S, "Defibrotide for the treatment of hepatic veno-occlusive disease : final results from the International Compassionate-Use Program", Biol Blood Marrow Transplant, 22, pp.1874~1882 (2016)
- Kernan NA, "Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease", sinusoidal obstruction syndrome, 2018, pp.181, 816~827
- Park M, "Safety and effects of prophylactic defibrotide for sinusoidal obstruction syndrome in hematopoietic stem cell transplantation", Ann Transplant, 18, pp.36~42 (2013)
- Corbacioglu S, "Defibrotide in the treatment of children with veno-occlusive disease(VOD) : a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention", Bone Marrow Transplant, 33, pp.189~195 (2004)
- Carreras E, "How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation", Br J Haematol, 168, pp.481~491 (2015)
- Jones RJ, "Venoocclusive disease of the liver following bone marrow transplantation", Transplantation, 44, pp.778~783 (1987)
- McDonald GB, "Venocclusive disease of the liver after bone marrow transplantation : diagnosis, incidence, and predisposing factors", Hepatology, 4, pp.116~122 (1984)
- Mohty M, "Revised diagnosis and severity criteria for sinusoidal obstruction syndrome", veno-occlusive disease in adult patients : a new classification from the European Society for Blood and Marrow Transplantation, 2016, pp.51, 906~912
- Richardson P, "Systematic review of defibrotide studies in the treatment of veno-occlusive disease", sinusoidal obstruction syndrome(VOD, Bone Marrow Transplant, pp.2019, 54[DOI]
- Corbacioglu S, "Incidence of anicteric veno-occlusive disease", sinusoidal obstruction syndrome and outcomes with defibrotide following hematopoietic cell transplantation in adult and pediatric patients, 2020, pp.26, 1342~1349
- Blostein MD, "A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation", Bone Marrow Transplant, 10, pp.439~443 (1992)
- Carreras E, "The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade", Biol Blood Marrow Transplant, 17, pp.1713~1720 (2011)
- Corbacioglu S, "Diagnosis and severity criteria for sinusoidal obstruction syndrome", veno-occlusive disease in pediatric patients : a new classification from the European society for blood and marrow transplantation, 2018, pp.53, 138~145
- Kammersgaard MB, "Assessment of the proposed EBMT pediatric criteria for diagnosis and severity grading of sinusoidal obstruction syndrome", Bone Marrow Transplant, 54, pp.1406~1418 (2019)
- Ragoonanan D, "Improved detection of sinusoidal obstructive syndrome using pediatric-AYA diagnostic criteria and severity grading", Bone Marrow Transplant, 56, pp.175~184 (2021)
- Fink JC, "Marked enzymuria after bone marrow transplantation : a correlate of veno-occlusive disease-induced"hepatorenal syndrome"", J Am Soc Nephrol, 6, pp.1655~1660 (1995)
- Chalandon Y, "Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation", Biol Blood Marrow Transplant, 10, pp.347~354 (2004)
- Aziz MT, "Defibrotide : an oligonucleotide for sinusoidal obstruction syndrome", Ann Pharmacother, 52, pp.166~174 (2018)
- Tekgunduz E, "Does defibrotide prophylaxis decrease the risk of acute graft versus host disease following allogeneic hematopoietic cell transplantation?", Transfus Apher Sci, 54, pp.30~34 (2016)
- Richardson PG, "Earlier defibrotide initiation post-diagnosis of veno-occlusive disease", sinusoidal obstruction syndrome improves day +100 survival following haematopoietic stem cell transplantation, 2017, pp.178, 112~118